[시장보고서]울토미리스약 시장 규모, 점유율, 동향 분석 리포트 : 적응증별, 최종 용도별, 유통 채널별, 지역별, 부문 예측(2025-2030년)

울토미리스약 시장 규모, 점유율, 동향 분석 리포트 : 적응증별, 최종 용도별, 유통 채널별, 지역별, 부문 예측(2025-2030년)

Ultomiris Drug Market Size, Share & Trends Analysis Report By Indication (PNH, Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorder), By End Use, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

상품코드 : 1751212

리서치사 : Grand View Research, Inc.

발행일 : 2025년 05월

페이지 정보 : 영문 150 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,158,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 9,529,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 12,271,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

울토미리스약 시장의 요약

세계의 울토미리스약 시장 규모는 2024년에 39억 2,000만 달러로 추계되며, 2025-2030년에 28.47%의 CAGR로 성장하며, 2030년에는 180억 3,000만 달러에 달할 것으로 예측됩니다. 세계 유르토미리스(라브릴주맙) 의약품 산업은 희귀질환의 장기 지속형 치료제에 대한 수요 증가로 인해 강한 추진력을 보이고 있습니다.

기존 솔리리스에 비해 투여 간격이 연장되어 편의성이 높아졌고, 환자의 순응도가 높아졌습니다. 이 때문에 발작성야간혈색소뇨증(PNH), 비정형 용혈성 요독 증후군(aHUS) 등의 질환을 관리하는 의료진들 사이에서 선호도가 높아지고 있습니다. 알렉시온은 미국과 유럽을 포함한 주요 시장에서 PNH 환자의 70% 이상이 솔리리스에서 유르토미리스로 전환했다고 밝혔습니다. 기존 보체 억제제에서 라불리주맙으로의 전환은 전체 시장 확대에 기여하고 있습니다.

또한 전신성 중증 근무력증(gMG)과 같은 새로운 적응증에서 임상적 유용성이 확대되고 있는 것도 성장에 박차를 가하고 있습니다. 예를 들어 유르토미리스는 지난 9월 유럽위원회로부터 항아세틸콜린 수용체 항체 양성 중증 근무력증(gMG) 성인 환자 치료제로 승인을 받아 신경과 영역에서의 입지를 강화하고 있습니다.

희귀 자가면역질환 및 혈액질환의 유병률 증가도 울토미리스 수요를 촉진하는 주요 요인입니다. 진단 툴의 개선과 임상 가이드라인의 업데이트로 대상 환자군을 조기에 파악할 수 있게 되었습니다. 예를 들어 2024년 3월 FDA는 시신경척수염 스펙트럼 장애(NMOSD) 치료제로서 유르토미리스에 대한 우선 심사권을 부여하여 파이프라인의 강점을 강조했습니다. 아스트라제네카와 알렉시온의 전략적 마케팅 노력과 파트너십은 임상의와 치료 센터의 인지도를 높이는 데 도움이 되고 있습니다. 이러한 요소들이 결합되며, 2030년까지 지속적인 매출 성장을 위한 유리한 환경을 조성하고 있습니다.

적응증별 시장 점유율, 2024년 및 2030년
적응증별 부문 대시보드
시장 규모, 예측, 동향 분석(적응증별, 2018-2030년)
발작성야간혈색소뇨증(PNH)
비전형 용혈성 요독증증후군(aHUS)
전신성 중증근무력증(gMG)
시신경 척수염 스펙트럼 장애(NMOSD)

제5장 울토미리스(Ravulizumab) 약 시장 : 최종 용도별 비즈니스 분석

최종 용도별 시장 점유율, 2024년 및 2030년
최종 용도별 부문 대시보드
시장 규모, 예측, 동향 분석(최종 용도별, 2018-2030년)
성인
소아과

제6장 울토미리스(Ravulizumab) 약 시장 : 유통 채널별 비즈니스 분석

유통 채널별 시장 점유율, 2024년 및 2030년
유통 채널별 부문 대시보드
시장 규모, 예측, 동향 분석(유통 채널별, 2018-2030년)
병원 약국
소매 약국
온라인 약국

제7장 울토미리스(Ravulizumab) 약 시장 : 지역별 추정·동향 분석

지역별 시장 점유율 분석, 2024년 및 2030년
지역별 시장 대시보드
시장 규모와 예측 동향 분석, 2018-2030년 :
북미
- 국가별, 2018-2030년
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트

제8장 경쟁 구도

전략 지도제작
기업 개요/상장기업
- AstraZeneca

KSA

영문 목차

영문목차

Ultomiris Drug Market Summary

The global ultomiris drug market size was estimated at USD 3.92 billion in 2024 and is projected to reach USD 18.03 billion by 2030, growing at a CAGR of 28.47% from 2025 to 2030. The global Ultomiris (ravulizumab) drug industry is experiencing strong momentum due to the rising demand for long-acting treatments in rare disorders.

Compared to its predecessor, Soliris, the drug's extended dosing interval offers convenience and improved patient compliance. This has increased preference among healthcare providers managing conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Alexion reported that over 70% of PNH patients had transitioned to Ultomiris from Soliris in major markets, including the U.S. and EU. The transition from older complement inhibitors to ravulizumab contributes to overall market expansion.

Growth is further fueled by its expanding clinical utility across new indications such as generalized myasthenia gravis (gMG). For instance, in September 2022, Ultomiris received approval from the European Commission to treat adult patients with anti-acetylcholine receptor antibody-positive gMG, strengthening its position in the neurology segment.

The rising incidence of rare autoimmune and hematologic conditions is also a major factor driving demand for Ultomiris. Improved diagnostic tools and updated clinical guidelines have identified eligible patient populations earlier. For instance, in March 2024, the FDA granted priority review to Ultomiris for its potential use in treating neuromyelitis optica spectrum disorder (NMOSD), highlighting its pipeline strength. Strategic marketing efforts and partnerships by AstraZeneca and Alexion have helped expand awareness among clinicians and treatment centers. These combined elements shape a favorable environment for sustained revenue growth through 2030.

Global Ultomiris Drug Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global Ultomiris (ravulizumab) drug market report based on indication, end use, distribution channel, and region:

Indication Outlook (Revenue, USD Million, 2018 - 2030)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Atypical Hemolytic Uremic Syndrome (aHUS)
Generalized Myasthenia Gravis (gMG)
Neuromyelitis Optica Spectrum Disorder (NMOSD)
End Use Outlook (Revenue, USD Million, 2018 - 2030)
Adult
Pediatric
Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Indication
- 1.2.2. End Use
- 1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information Analysis
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Ultomiris (Ravulizumab) Drug Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis

Chapter 4. Ultomiris (Ravulizumab) Drug Market: Indication Business Analysis

4.1. Indication Market Share, 2024 & 2030
4.2. Indication Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
4.4. Paroxysmal Nocturnal Hemoglobinuria (PNH)
- 4.4.1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, 2018 - 2030 (USD Million)
4.5. Atypical Hemolytic Uremic Syndrome (aHUS)
- 4.5.1. Atypical Hemolytic Uremic Syndrome (aHUS) Market, 2018 - 2030 (USD Million)
4.6. Generalized Myasthenia Gravis (gMG)
- 4.6.1. Generalized Myasthenia Gravis (gMG) Market, 2018 - 2030 (USD Million)
4.7. Neuromyelitis Optica Spectrum Disorder (NMOSD)
- 4.7.1. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, 2018 - 2030 (USD Million)

Chapter 5. Ultomiris (Ravulizumab) Drug Market: End Use Business Analysis

5.1. End Use Market Share, 2024 & 2030
5.2. End Use Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
5.4. Adult
- 5.4.1. Adult Market, 2018 - 2030 (USD Million)
5.5. Pediatric
- 5.5.1. Pediatric Market, 2018 - 2030 (USD Million)

Chapter 6. Ultomiris (Ravulizumab) Drug Market: Distribution Channel Business Analysis

6.1. Distribution Channel Market Share, 2024 & 2030
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
6.4. Hospital Pharmacies
- 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
6.5. Retail Pharmacies
- 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
6.6. Online Pharmacies
- 6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Ultomiris (Ravulizumab) Drug Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
- 7.4.1. North America Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
- 7.4.2. U.S.
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Target Disease Prevalence
  - 7.4.2.3. Regulatory Framework
  - 7.4.2.4. Reimbursement Framework
  - 7.4.2.5. U.S. Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Canada
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Target Disease Prevalence
  - 7.4.3.3. Regulatory Framework
  - 7.4.3.4. Reimbursement Framework
  - 7.4.3.5. U.S. Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. Mexico
  - 7.4.4.1. Key Country Dynamics
  - 7.4.4.2. Target Disease Prevalence
  - 7.4.4.3. Regulatory Framework
  - 7.4.4.4. Reimbursement Framework
  - 7.4.4.5. Mexico Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Europe
- 7.5.1. Europe Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. UK
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Target Disease Prevalence
  - 7.5.2.3. Regulatory Framework
  - 7.5.2.4. Reimbursement Framework
  - 7.5.2.5. Uk Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Germany
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Target Disease Prevalence
  - 7.5.3.3. Regulatory Framework
  - 7.5.3.4. Reimbursement Framework
  - 7.5.3.5. Germany Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.4. France
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Target Disease Prevalence
  - 7.5.4.3. Regulatory Framework
  - 7.5.4.4. Reimbursement Framework
  - 7.5.4.5. France Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.5. Italy
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Target Disease Prevalence
  - 7.5.5.3. Regulatory Framework
  - 7.5.5.4. Reimbursement Framework
  - 7.5.5.5. Italy Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.6. Spain
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Target Disease Prevalence
  - 7.5.6.3. Regulatory Framework
  - 7.5.6.4. Reimbursement Framework
  - 7.5.6.5. Spain Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.7. Denmark
  - 7.5.7.1. Key Country Dynamics
  - 7.5.7.2. Target Disease Prevalence
  - 7.5.7.3. Regulatory Framework
  - 7.5.7.4. Reimbursement Framework
  - 7.5.7.5. Denmark Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.8. Sweden
  - 7.5.8.1. Key Country Dynamics
  - 7.5.8.2. Target Disease Prevalence
  - 7.5.8.3. Regulatory Framework
  - 7.5.8.4. Reimbursement Framework
  - 7.5.8.5. Sweden Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.9. Norway
  - 7.5.9.1. Key Country Dynamics
  - 7.5.9.2. Target Disease Prevalence
  - 7.5.9.3. Regulatory Framework
  - 7.5.9.4. Reimbursement Framework
  - 7.5.9.5. Norway Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Asia Pacific
- 7.6.1. Asia Pacific Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Japan
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Target Disease Prevalence
  - 7.6.2.3. Regulatory Framework
  - 7.6.2.4. Reimbursement Framework
  - 7.6.2.5. Japan Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. China
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Target Disease Prevalence
  - 7.6.3.3. Regulatory Framework
  - 7.6.3.4. Reimbursement Framework
  - 7.6.3.5. China Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. India
  - 7.6.4.1. Key Country Dynamics
  - 7.6.4.2. Target Disease Prevalence
  - 7.6.4.3. Regulatory Framework
  - 7.6.4.4. Reimbursement Framework
  - 7.6.4.5. India Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Australia
  - 7.6.5.1. Key Country Dynamics
  - 7.6.5.2. Target Disease Prevalence
  - 7.6.5.3. Regulatory Framework
  - 7.6.5.4. Reimbursement Framework
  - 7.6.5.5. Australia Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.6. South Korea
  - 7.6.6.1. Key Country Dynamics
  - 7.6.6.2. Target Disease Prevalence
  - 7.6.6.3. Regulatory Framework
  - 7.6.6.4. Reimbursement Framework
  - 7.6.6.5. South Korea Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.7. Thailand
  - 7.6.7.1. Key Country Dynamics
  - 7.6.7.2. Target Disease Prevalence
  - 7.6.7.3. Regulatory Framework
  - 7.6.7.4. Reimbursement Framework
  - 7.6.7.5. Thailand Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7. Latin America
- 7.7.1. Latin America Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.2. Brazil
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Target Disease Prevalence
  - 7.7.2.3. Regulatory Framework
  - 7.7.2.4. Reimbursement Framework
  - 7.7.2.5. Japan Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.3. Argentina
  - 7.7.3.1. Key Country Dynamics
  - 7.7.3.2. Target Disease Prevalence
  - 7.7.3.3. Regulatory Framework
  - 7.7.3.4. Reimbursement Framework
  - 7.7.3.5. China Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2017 - 2030 (USD Million)
- 7.8.2. South Africa
  - 7.8.2.1. Key Country Dynamics
  - 7.8.2.2. Target Disease Prevalence
  - 7.8.2.3. Regulatory Framework
  - 7.8.2.4. Reimbursement Framework
  - 7.8.2.5. South Africa Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.3. Saudi Arabia
  - 7.8.3.1. Key Country Dynamics
  - 7.8.3.2. Target Disease Prevalence
  - 7.8.3.3. Regulatory Framework
  - 7.8.3.4. Reimbursement Framework
  - 7.8.3.5. Saudi Arabia Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.4. UAE
  - 7.8.4.1. Key Country Dynamics
  - 7.8.4.2. Target Disease Prevalence
  - 7.8.4.3. Regulatory Framework
  - 7.8.4.4. Reimbursement Framework
  - 7.8.4.5. UAE Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.5. Kuwait
  - 7.8.5.1. Key Country Dynamics
  - 7.8.5.2. Target Disease Prevalence
  - 7.8.5.3. Regulatory Framework
  - 7.8.5.4. Reimbursement Framework
  - 7.8.5.5. Kuwait Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Strategy Mapping
8.2. Company Profiles/Listing
- 8.2.1. AstraZeneca
  - 8.2.1.1. Overview
  - 8.2.1.2. Financial Performance
  - 8.2.1.3. Product Benchmarking
  - 8.2.1.4. Strategic Initiatives